XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Changes in Redeemable Noncontrolling Interest, Convertible Preferred Shares, and Shareholders' Equity (Deficit) - USD ($)
$ in Thousands
Noncontrolling interest
Class A Ordinary Shares
Additional Paid-in Capital
Accumulated Deficit
Redeemable Noncontrolling Interest
Convertible Preferred Shares
License agreement with Lilly
Total
Balance (Shares) at Dec. 31, 2022           13,510,415    
Balance at Dec. 31, 2022         $ 10,000 $ 12,500 [1]    
Convertible Preferred Shares                
Issuance of Series A-1 convertible preferred shares as license compensation [1]           $ 2,186    
Issuance of Series A-1 convertible preferred shares as license compensation (in shares)           267,939    
Conversion of Series A-1 convertible preferred shares to Class A Ordinary Shares in connection with Business Combination   $ (2) [1] $ (14,684)     $ (14,686) [1]   $ (14,686)
Conversion of Series A-1 convertible preferred shares to Class A Ordinary Shares in connection with Business Combination (in shares)   (13,778,354)       (13,778,354)    
Accretion of redeemable noncontrolling interest to redemption value       $ 203 203     203
Issuance of Series A-1 convertible preferred shares as license compensation [1]           $ 2,186    
Net Income (Loss)       (9,592) (203)     (9,592)
Balance at Mar. 31, 2023         10,000      
Beginning Balance (in shares) at Dec. 31, 2022   279,720            
Balance at Dec. 31, 2022       (32,056)       (32,056)
Increase (Decrease) in Stockholders' Deficit                
Conversion of Series A-1 convertible preferred shares to Class A Ordinary Shares in connection with Business Combination   $ 2 [1] 14,684     $ 14,686 [1]   14,686
Conversion of Series A-1 convertible preferred shares to Class A Ordinary Shares in connection with Business Combination (in shares)   13,778,354       13,778,354    
Issuance of Class A Ordinary Shares in connection with Business Combination, including PIPE Investment, Forward Purchase Investment, and Backstop Shares, net of $4.0 million of transaction costs   $ 1 [1] 48,350         48,351
Issuance of Class A Ordinary Shares in connection with Business Combination, including PIPE Investment, Forward Purchase Investment, and Backstop Shares (in shares)   12,444,081            
Issuance of Class A Ordinary Shares to settle research and development license consideration liability     4,488         4,488
Issuance of Class A Ordinary Shares to settle research and development license consideration liability (in shares)   550,000            
Reclassification of public warrant liability to equity     2,001         2,001
Share-based compensation expense     180         180
Net Income (Loss)       (9,592) (203)     (9,592)
Accretion of redeemable noncontrolling interest to redemption value       (203) (203)     (203)
Ending Balance (in Shares) at Mar. 31, 2023   27,052,155            
Balance at Mar. 31, 2023   $ 3 [1] 69,703 (41,851)       27,855
Balance (Shares) at Dec. 31, 2022           13,510,415    
Balance at Dec. 31, 2022         10,000 $ 12,500 [1]    
Balance at Dec. 31, 2023         18,680      
Beginning Balance (in shares) at Dec. 31, 2022   279,720            
Balance at Dec. 31, 2022       (32,056)       $ (32,056)
Increase (Decrease) in Stockholders' Deficit                
Issuance of Class A Ordinary Shares to settle research and development license consideration liability (in shares)             33  
Ending Balance (in Shares) at Dec. 31, 2023   43,593,678           43,593,678
Balance at Dec. 31, 2023 $ 1,541 $ 4 [1] 162,820 (103,494)       $ 60,871
Convertible Preferred Shares                
Adjustment of redeemable noncontrolling interest from redemption value to carrying value     7,017   (7,017)     7,017
Net Income (Loss)       (7,747)       (7,747)
Balance at Mar. 31, 2024         11,663      
Increase (Decrease) in Stockholders' Deficit                
Share-based compensation expense     2,409         2,409
Net Income (Loss)       (7,747)       (7,747)
Adjustment of redeemable noncontrolling interest from redemption value to carrying value     7,017   $ (7,017)     $ 7,017
Ending Balance (in Shares) at Mar. 31, 2024   43,593,678           43,593,678
Balance at Mar. 31, 2024 $ 1,541 $ 4 [1] $ 172,246 $ (111,241)       $ 62,550
[1] The Company’s convertible preferred shares and Class A Ordinary Shares prior to the closing of the Business Combination (as defined in Note 1) have been retroactively restated to reflect the exchange ratio of approximately 108.083 established in the Business Combination Agreement as described in Note